Alterity Therapeutics(US:ATHE) Newsfilter·2024-01-29 12:24Core Viewpoint - Alterity Therapeutics is actively engaging with investors and the public through a webinar to discuss its developments in neurodegenerative disease treatments, particularly focusing on its lead asset, ATH434 [1][2]. Group 1: Company Overview - Alterity Therapeutics is a clinical stage biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases [2]. - The company's lead asset, ATH434, has potential applications in treating various Parkinsonian disorders [2]. - Alterity operates from Melbourne, Australia, and San Francisco, California, USA [2]. Group 2: Event Participation - David Stamler, M.D., the CEO of Alterity, will participate in the ShareCafe Hidden Gems webinar on February 2, 2024, for Australian participants and February 1, 2024, for U.S. participants [1]. - The webinar is free to register, and an archived replay will be available after the event [1].